Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Amylyx Pharmaceuticals, Inc. (AMLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Zacks Equity Research

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.

Zacks Equity Research

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Zacks Equity Research

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Zacks Equity Research

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Zacks Equity Research

Elevance Health (ELV) Beats Q3 Earnings, Hikes '23 Profit View

by Zacks Equity Research

Elevance Health's (ELV) Q3 results gain on growing medical customer base and strong pharmacy product revenues. Adjusted net income is currently projected to be more than $33.00 per share for 2023.

Tirthankar Chakraborty headshot

3 Solid Stocks to Buy for Superb Earnings Acceleration

by Tirthankar Chakraborty

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

Zacks Equity Research

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI